Sangamo Therapeutics (NASDAQ:SGMO) has been given a $25.00 price target by stock analysts at Piper Jaffray Companies in a research note issued on Wednesday, January 3rd. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Piper Jaffray Companies’ price objective would suggest a potential upside of 36.61% from the company’s previous close.
Several other analysts also recently issued reports on the stock. Wells Fargo & Co reaffirmed an “outperform” rating and issued a $30.00 price objective (up previously from $20.00) on shares of Sangamo Therapeutics in a research report on Tuesday, September 5th. Barclays initiated coverage on shares of Sangamo Therapeutics in a research report on Wednesday, November 22nd. They issued an “overweight” rating and a $20.00 price objective for the company. Zacks Investment Research raised shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price objective for the company in a research report on Wednesday, November 15th. Wedbush reaffirmed a “hold” rating and issued a $6.00 price objective on shares of Sangamo Therapeutics in a research report on Wednesday, November 15th. Finally, Jefferies Group reaffirmed a “buy” rating and issued a $18.00 price objective on shares of Sangamo Therapeutics in a research report on Thursday, September 14th. Four equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $18.83.
Sangamo Therapeutics (NASDAQ SGMO) opened at $18.30 on Wednesday. The firm has a market cap of $1,449.53, a PE ratio of -26.52 and a beta of 3.16. Sangamo Therapeutics has a 1-year low of $3.35 and a 1-year high of $18.69. The company has a current ratio of 5.64, a quick ratio of 5.64 and a debt-to-equity ratio of 0.02.
Sangamo Therapeutics (NASDAQ:SGMO) last posted its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.19) by $0.04. The firm had revenue of $11.81 million during the quarter, compared to the consensus estimate of $10.37 million. Sangamo Therapeutics had a negative net margin of 157.66% and a negative return on equity of 31.81%. The company’s revenue was up 333.0% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.27) EPS. research analysts anticipate that Sangamo Therapeutics will post -0.73 earnings per share for the current year.
In other news, Director Saira Ramasastry sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, November 17th. The shares were sold at an average price of $14.67, for a total transaction of $73,350.00. Following the completion of the sale, the director now owns 5,000 shares of the company’s stock, valued at $73,350. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Curt A. Herberts III sold 16,630 shares of the firm’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $16.13, for a total transaction of $268,241.90. The disclosure for this sale can be found here. Insiders sold 58,433 shares of company stock valued at $979,696 in the last ninety days. 5.50% of the stock is owned by corporate insiders.
Hedge funds have recently added to or reduced their stakes in the company. Cookson Peirce & Co. Inc. acquired a new stake in shares of Sangamo Therapeutics during the second quarter worth approximately $317,000. State Street Corp grew its position in shares of Sangamo Therapeutics by 51.6% during the second quarter. State Street Corp now owns 1,868,285 shares of the biopharmaceutical company’s stock worth $16,441,000 after buying an additional 636,296 shares in the last quarter. Swiss National Bank grew its position in shares of Sangamo Therapeutics by 26.4% during the second quarter. Swiss National Bank now owns 143,560 shares of the biopharmaceutical company’s stock worth $1,263,000 after buying an additional 30,000 shares in the last quarter. Goldman Sachs Group Inc. grew its position in shares of Sangamo Therapeutics by 53.5% during the second quarter. Goldman Sachs Group Inc. now owns 100,176 shares of the biopharmaceutical company’s stock worth $881,000 after buying an additional 34,913 shares in the last quarter. Finally, Wells Fargo & Company MN grew its position in shares of Sangamo Therapeutics by 45.8% during the second quarter. Wells Fargo & Company MN now owns 431,234 shares of the biopharmaceutical company’s stock worth $3,795,000 after buying an additional 135,464 shares in the last quarter. 64.33% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: “Sangamo Therapeutics (NASDAQ:SGMO) Given a $25.00 Price Target by Piper Jaffray Companies Analysts” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2018/01/13/piper-jaffray-companies-reiterates-25-00-price-target-for-sangamo-therapeutics-sgmo.html.
Sangamo Therapeutics Company Profile
Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.